Pesquisas alternativas:
doses develop » loss develop (Expandir a Pesquisa), models develop (Expandir a Pesquisa), locus develop (Expandir a Pesquisa)
develop type » developing type (Expandir a Pesquisa)
novel ther » novel ether (Expandir a Pesquisa), novel thr (Expandir a Pesquisa), novel theory (Expandir a Pesquisa)
drug doses » drug dose (Expandir a Pesquisa), drug disease (Expandir a Pesquisa)
de novel » de novela (Expandir a Pesquisa), de nove (Expandir a Pesquisa), fe novel (Expandir a Pesquisa)
drug de » drug dose (Expandir a Pesquisa), drug deal (Expandir a Pesquisa), drug dna (Expandir a Pesquisa)
doses develop » loss develop (Expandir a Pesquisa), models develop (Expandir a Pesquisa), locus develop (Expandir a Pesquisa)
develop type » developing type (Expandir a Pesquisa)
novel ther » novel ether (Expandir a Pesquisa), novel thr (Expandir a Pesquisa), novel theory (Expandir a Pesquisa)
drug doses » drug dose (Expandir a Pesquisa), drug disease (Expandir a Pesquisa)
de novel » de novela (Expandir a Pesquisa), de nove (Expandir a Pesquisa), fe novel (Expandir a Pesquisa)
drug de » drug dose (Expandir a Pesquisa), drug deal (Expandir a Pesquisa), drug dna (Expandir a Pesquisa)
1
Por Hansen, Aaron R., Cook, Natalie, Ricci, M. Stacey, Razak, Albiruni, Le Tourneau, Christophe, McKeever, Kathleen, Roskos, Lorin, Dixit, Rakesh, Siu, Lillian L., Hinrichs, Mary Jane
Publicado no Oncologist (2015)
Assuntos:
“...New Drug Development and Clinical Pharmacology...”Publicado no Oncologist (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
2
Por Gisslinger, Heinz, Zagrijtschuk, Oleh, Buxhofer-Ausch, Veronika, Thaler, Josef, Schloegl, Ernst, Gastl, Guenther A., Wolf, Dominik, Kralovics, Robert, Gisslinger, Bettina, Strecker, Karin, Egle, Alexander, Melchardt, Thomas, Burgstaller, Sonja, Willenbacher, Ella, Schalling, Martin, Them, Nicole C., Kadlecova, Pavla, Klade, Christoph, Greil, Richard
Publicado no Blood (2015)
“... and safety of ropeginterferon alfa-2b and support the development of the drug in a randomized phase 3...”Publicado no Blood (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
3
Por Tácio de Mendonça Lima, Millena Padela da Silva, Luan Donato Silva Luz, Thais Cristina Amorim Estevão Soares, Etielle Silvestre Dantas, Gabriela Felix Teixeira, Rafael Henrique de Souza Costa, Sérgio Henrique Monte Santo Andrade
Publicado em 2022-03-01
Assuntos:
“...Drug dosage calculation...”Publicado em 2022-03-01
Obter o texto integral
Artigo
4
“...Identification of novel targets is a critical first step in the drug discovery and development...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
Por Wang, Wei-Peng, Ho, Pui Yan, Chen, Qiu-Xia, Addepalli, Balasubrahmanyam, Limbach, Patrick A., Li, Mei-Mei, Wu, Wen-Juan, Jilek, Joseph L., Qiu, Jing-Xin, Zhang, Hong-Jian, Li, Tianhong, Wun, Theodore, White, Ralph DeVere, Lam, Kit S., Yu, Ai-Ming
Publicado no J Pharmacol Exp Ther (2015)
Assuntos:
“...Drug Discovery and Translational Medicine...”Publicado no J Pharmacol Exp Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
6
“... pharmacokinetics and pharmacodynamics, and they frequently interact with food and other drugs, requiring...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
7
Por van Rijn, Richard M., Harvey, Jessica H., Brissett, Daniela I., DeFriel, Julia N., Whistler, Jennifer L.
Publicado em 2013
Assuntos:
“...Drug Discovery and Translational Medicine...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
“...<p>Abstract</p> <p>Background</p> <p>Type 2 diabetes is a risk factor for Alzheimer's disease (AD...”
Obter o texto integral
Obter o texto integral
Artigo
9
“... drugs were able to cross the BBB. Lixisenatide crossed the BBB at all doses tested (2.5, 25, or 250 nmol...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
Por Chism, David D., De Silva, Dinuka, Whang, Young E.
Publicado no Expert Rev Anticancer Ther (2014)
“... receptors such as glucocorticoid receptor may substitute for androgen receptor. Drugs with novel mechanisms...”Publicado no Expert Rev Anticancer Ther (2014)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
11
Por Heredia, Alonso, Latinovic, Olga S, Barbault, Florent, de Leeuw, Erik PH
Publicado no Drug Des Devel Ther (2015)
“... options due to HIV-1 resistance, side effects, or drug costs. Further, it is likely that current drugs...”Publicado no Drug Des Devel Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
Por Petta, Ioanna, Lievens, Sam, Libert, Claude, Tavernier, Jan, De Bosscher, Karolien
Publicado no Mol Ther (2016)
“... to investigate the unexplored potential of PPIs in drug discovery is driven by the need to find novel therapeutic...”Publicado no Mol Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
13
Por Berardi, Rossana, Santoni, Matteo, Morgese, Francesca, Ballatore, Zelmira, Savini, Agnese, Onofri, Azzurra, Mazzanti, Paola, Pistelli, Mirco, Pierantoni, Chiara, De Lisa, Mariagrazia, Caramanti, Miriam, Pagliaretta, Silvia, Pellei, Chiara, Cascinu, Stefano
Publicado em 2013
“...://www.clinicaltrials.gov), aimed to evaluate the efficacy and toxicity of combined approaches and to develop novel...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
Por Wang, Xue Yan, Lim-Jurado, Margaret, Prepageran, Narayanan, Tantilipikorn, Pongsakorn, Wang, De Yun
Publicado no Ther Clin Risk Manag (2016)
“... that it has very low potential for drug–drug interactions, and does not require dose adjustment in renal...”Publicado no Ther Clin Risk Manag (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
15
Por Renna, Antonio, Vejarano, L. Felipe, De la Cruz, Ernesto, Alió, Jorge L.
Publicado no Ophthalmol Ther (2016)
“...PURPOSE: The feasibility, in terms of safety and potential efficacy, of a new drug combination...”Publicado no Ophthalmol Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
Por Rossini, Maurizio, De Vita, Salvatore, Ferri, Clodoveo, Govoni, Marcello, Paolazzi, Giuseppe, Salvarani, Carlo, Adami, Silvano
Publicado em 2013
“... factor (TNF) administered monthly by subcutaneous injection. It is approved by the US Food and Drug...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Artigo
17
Por De Sensi, Francesco, De Potter, Tom, Cresti, Alberto, Severi, Silva, Breithardt, Günter
Publicado no Cardiovasc Diagn Ther (2015)
“... and their relevance for mechanism-based therapeutic strategies in this setting. Advances in risk stratification, drug...”Publicado no Cardiovasc Diagn Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
18
Por Salzano, Giuseppina, Navarro, Gemma, Trivedi, Malav S., De Rosa, Giuseppe, Torchilin, Vladimir P.
Publicado no Mol Cancer Ther (2015)
“... novel type of non-toxic and easy-to-obtain nano-device for the combined therapy of siRNA and anti-cancer...”Publicado no Mol Cancer Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
“... for drug development is hot news. When Cramer and colleagues proposed last year that they could tackle AD...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
“...-hydroxytryptamine receptor type 3 (5-HT3) blockers, making them preferred choices especially in cases of drug...”
Obter o texto integral
Obter o texto integral
Artigo